Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.
Placzke J, Rosińska M, Sobczuk P, Ziętek M, Kempa-Kamińska N, Cybulska-Stopa B, Kamińska-Winciorek G, Bal W, Mackiewicz J, Galus Ł, Las-Jankowska M, Jankowski M, Dziura R, Drucis K, Borkowska A, Świtaj T, Rogala P, Kozak K, Klimczak A, Jagodzińska-Mucha P, Szumera-Ciećkiewicz A, Koseła-Paterczyk H, Rutkowski P. Placzke J, et al. Among authors: jagodzinska mucha p. Cancers (Basel). 2023 Sep 1;15(17):4384. doi: 10.3390/cancers15174384. Cancers (Basel). 2023. PMID: 37686659 Free PMC article.
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
Teterycz P, Jagodzińska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, Kozak K, Koseła-Paterczyk H, Czarnecka AM, Rajczykowski M, Dziura R, Galus Ł, Mackiewicz J, Świtaj T, Klimczak A, Falkowski S, Suwiński R, Ziobro M, Ługowska I, Rutkowski P. Teterycz P, et al. Among authors: jagodzinska mucha p. Melanoma Res. 2018 Oct;28(5):435-441. doi: 10.1097/CMR.0000000000000461. Melanoma Res. 2018. PMID: 29782381
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study.
Cybulska-Stopa B, Ługowska I, Jagodzińska-Mucha P, Koseła-Paterczyk H, Kozak K, Klimczak A, Świtaj T, Ziobro M, Roman A, Rajczykowski M, Suwiński R, Niemiec M, Zemełka T, Falkowski S, Rutkowski P. Cybulska-Stopa B, et al. Among authors: jagodzinska mucha p. Postepy Dermatol Alergol. 2019 Oct;36(5):566-571. doi: 10.5114/ada.2018.79940. Epub 2019 Nov 12. Postepy Dermatol Alergol. 2019. PMID: 31839773 Free PMC article.
Mutational landscape of primary and recurrent Ewing sarcoma.
Jagodzińska-Mucha P, Sobczuk P, Mikuła M, Raciborska A, Dawidowska A, Kulecka M, Bilska K, Szumera-Ciećkiewicz A, Kluska A, Piątkowska M, Bałabas A, Rutkowski P, Ługowska I. Jagodzińska-Mucha P, et al. Contemp Oncol (Pozn). 2021;25(4):241-248. doi: 10.5114/wo.2021.112234. Epub 2021 Dec 29. Contemp Oncol (Pozn). 2021. PMID: 35079231 Free PMC article.
What role can LAG-3-blocking antibodies play in melanoma therapy?
Rutkowski P, Jagodzińska-Mucha P. Rutkowski P, et al. Among authors: jagodzinska mucha p. Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1155-1158. doi: 10.1080/14712598.2023.2281495. Epub 2023 Dec 28. Expert Opin Biol Ther. 2023. PMID: 37936502 No abstract available.
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
Hindi N, Razak A, Rosenbaum E, Jonczak E, Hamacher R, Rutkowski P, Bhadri VA, Skryd A, Brahmi M, Alshibany A, Jagodzinska-Mucha P, Bauer S, Connolly E, Gelderblom H, Boye K, Henon C, Bae S, Bogefors K, Vincenzi B, Martinez-Trufero J, Lopez-Martin JA, Redondo A, Valverde C, Blay JY, Moura DS, Gutierrez A, Tap W, Martin-Broto J. Hindi N, et al. Among authors: jagodzinska mucha p. ESMO Open. 2023 Dec;8(6):102045. doi: 10.1016/j.esmoop.2023.102045. Epub 2023 Nov 27. ESMO Open. 2023. PMID: 38016251 Free PMC article.